In the next 3-5 years, Bayer intends to raise the share of its localized products in Russia to 30% of the total sales of the company. The company is already implementing a number of large-scale projects to localize the manufacturing of innovative medicines, said Nils Hessmann, General Representative of Bayer in Russia and CIS.
“In Russia, Bayer is actively developing the localization strategy to improve the availability of innovative solutions. In the next 3-5 years, our goal is to raise the share of localized products to 30% of the total sales of the company,” said Nils Hessmann.
He added that, as part of cooperation with Polisan, Bayer plans to start the industrial manufacturing of X-ray contrast agents in Q4 2018. The production of Bayer’s oral anticoagulant is expected to begin in Q3-Q4, 2020.
General representative of Bayer in Russia also spoke about its collaboration with young Russian companies that are implementing projects in the area of medical technology.
“CoLaborator, a program that was launched last year after signing a cooperation agreement with the Faculty of Biology of the Moscow State University, involves three selected promising Russian projects aimed at developing advanced medical technology to combat cancer and cardiovascular diseases. For each project, Bayer will provide financial support in the amount of 25 thousand euro,” said Nils Hessmann.